Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines

Matthew S. Robbins, Amaal J. Starling, Tamara M. Pringsheim, Werner J. Becker, Todd J. Schwedt

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

Background: Cluster headache (CH), the most common trigeminal autonomic cephalalgia, is an extremely debilitating primary headache disorder that is often not optimally treated. New evidence-based treatment guidelines for CH will assist clinicians with identifying and choosing among current treatment options. Objectives: In this systematic review we appraise the available evidence for the acute and prophylactic treatment of CH, and provide an update of the 2010 American Academy of Neurology (AAN) endorsed systematic review. Methods: Medline, PubMed, and EMBASE databases were searched for double-blind, randomized controlled trials that investigated treatments of CH in adults. Exclusion and inclusion criteria were identical to those utilized in the 2010 AAN systematic review. Results and Recommendations: For acute treatment, sumatriptan subcutaneous, zolmitriptan nasal spray, and high flow oxygen remain the treatments with a Level A recommendation. Since the 2010 review, a study of sphenopalatine ganglion stimulation was added to the current guideline and has been administered a Level B recommendation for acute treatment. For prophylactic therapy, previously there were no treatments that were administered a Level A recommendation. For the current guidelines, suboccipital steroid injections have emerged as the only treatment to receive a Level A recommendation with the addition of a second Class I study. Other newly evaluated treatments since the 2010 guidelines have been given a Level B recommendation (negative study: deep brain stimulation), a Level C recommendation (positive study: warfarin; negative studies: cimetidine/chlorpheniramine, candesartan), or a Level U recommendation (frovatriptan). Conclusions: This AHS guideline can be utilized for understanding which therapies have superiority to placebo or sham treatment in the management of CH. In clinical practice, these recommendations should be considered in concert with other variables including safety, side effects, patient preferences, clinician experience, cost, and the invasiveness of the intervention. Given the lack of Class I evidence and Level A recommendations, particularly for a number of commonly used preventive therapies, further studies are warranted to demonstrate safety and efficacy for established and emerging therapies.

Original languageEnglish (US)
Pages (from-to)1093-1106
Number of pages14
JournalHeadache
Volume56
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Cluster Headache
Guidelines
Therapeutics
zolmitriptan
Placebos
Primary Headache Disorders
Chlorpheniramine
Sumatriptan
Nasal Sprays
Safety
Deep Brain Stimulation
Patient Preference
Cimetidine
Warfarin
Neurology
PubMed
Ganglia

Keywords

  • calcium-channel blockers
  • chronic
  • cluster
  • episodic
  • evidence-based medicine
  • guidelines
  • headache
  • lithium
  • neurostimulation
  • oxygen
  • sphenopalatine
  • verapamil

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Robbins, M. S., Starling, A. J., Pringsheim, T. M., Becker, W. J., & Schwedt, T. J. (2016). Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache, 56(7), 1093-1106. https://doi.org/10.1111/head.12866

Treatment of Cluster Headache : The American Headache Society Evidence-Based Guidelines. / Robbins, Matthew S.; Starling, Amaal J.; Pringsheim, Tamara M.; Becker, Werner J.; Schwedt, Todd J.

In: Headache, Vol. 56, No. 7, 01.07.2016, p. 1093-1106.

Research output: Contribution to journalReview article

Robbins, MS, Starling, AJ, Pringsheim, TM, Becker, WJ & Schwedt, TJ 2016, 'Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines', Headache, vol. 56, no. 7, pp. 1093-1106. https://doi.org/10.1111/head.12866
Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016 Jul 1;56(7):1093-1106. https://doi.org/10.1111/head.12866
Robbins, Matthew S. ; Starling, Amaal J. ; Pringsheim, Tamara M. ; Becker, Werner J. ; Schwedt, Todd J. / Treatment of Cluster Headache : The American Headache Society Evidence-Based Guidelines. In: Headache. 2016 ; Vol. 56, No. 7. pp. 1093-1106.
@article{5b88838c35944747b51e70b498b735c4,
title = "Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines",
abstract = "Background: Cluster headache (CH), the most common trigeminal autonomic cephalalgia, is an extremely debilitating primary headache disorder that is often not optimally treated. New evidence-based treatment guidelines for CH will assist clinicians with identifying and choosing among current treatment options. Objectives: In this systematic review we appraise the available evidence for the acute and prophylactic treatment of CH, and provide an update of the 2010 American Academy of Neurology (AAN) endorsed systematic review. Methods: Medline, PubMed, and EMBASE databases were searched for double-blind, randomized controlled trials that investigated treatments of CH in adults. Exclusion and inclusion criteria were identical to those utilized in the 2010 AAN systematic review. Results and Recommendations: For acute treatment, sumatriptan subcutaneous, zolmitriptan nasal spray, and high flow oxygen remain the treatments with a Level A recommendation. Since the 2010 review, a study of sphenopalatine ganglion stimulation was added to the current guideline and has been administered a Level B recommendation for acute treatment. For prophylactic therapy, previously there were no treatments that were administered a Level A recommendation. For the current guidelines, suboccipital steroid injections have emerged as the only treatment to receive a Level A recommendation with the addition of a second Class I study. Other newly evaluated treatments since the 2010 guidelines have been given a Level B recommendation (negative study: deep brain stimulation), a Level C recommendation (positive study: warfarin; negative studies: cimetidine/chlorpheniramine, candesartan), or a Level U recommendation (frovatriptan). Conclusions: This AHS guideline can be utilized for understanding which therapies have superiority to placebo or sham treatment in the management of CH. In clinical practice, these recommendations should be considered in concert with other variables including safety, side effects, patient preferences, clinician experience, cost, and the invasiveness of the intervention. Given the lack of Class I evidence and Level A recommendations, particularly for a number of commonly used preventive therapies, further studies are warranted to demonstrate safety and efficacy for established and emerging therapies.",
keywords = "calcium-channel blockers, chronic, cluster, episodic, evidence-based medicine, guidelines, headache, lithium, neurostimulation, oxygen, sphenopalatine, verapamil",
author = "Robbins, {Matthew S.} and Starling, {Amaal J.} and Pringsheim, {Tamara M.} and Becker, {Werner J.} and Schwedt, {Todd J.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/head.12866",
language = "English (US)",
volume = "56",
pages = "1093--1106",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Treatment of Cluster Headache

T2 - The American Headache Society Evidence-Based Guidelines

AU - Robbins, Matthew S.

AU - Starling, Amaal J.

AU - Pringsheim, Tamara M.

AU - Becker, Werner J.

AU - Schwedt, Todd J.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: Cluster headache (CH), the most common trigeminal autonomic cephalalgia, is an extremely debilitating primary headache disorder that is often not optimally treated. New evidence-based treatment guidelines for CH will assist clinicians with identifying and choosing among current treatment options. Objectives: In this systematic review we appraise the available evidence for the acute and prophylactic treatment of CH, and provide an update of the 2010 American Academy of Neurology (AAN) endorsed systematic review. Methods: Medline, PubMed, and EMBASE databases were searched for double-blind, randomized controlled trials that investigated treatments of CH in adults. Exclusion and inclusion criteria were identical to those utilized in the 2010 AAN systematic review. Results and Recommendations: For acute treatment, sumatriptan subcutaneous, zolmitriptan nasal spray, and high flow oxygen remain the treatments with a Level A recommendation. Since the 2010 review, a study of sphenopalatine ganglion stimulation was added to the current guideline and has been administered a Level B recommendation for acute treatment. For prophylactic therapy, previously there were no treatments that were administered a Level A recommendation. For the current guidelines, suboccipital steroid injections have emerged as the only treatment to receive a Level A recommendation with the addition of a second Class I study. Other newly evaluated treatments since the 2010 guidelines have been given a Level B recommendation (negative study: deep brain stimulation), a Level C recommendation (positive study: warfarin; negative studies: cimetidine/chlorpheniramine, candesartan), or a Level U recommendation (frovatriptan). Conclusions: This AHS guideline can be utilized for understanding which therapies have superiority to placebo or sham treatment in the management of CH. In clinical practice, these recommendations should be considered in concert with other variables including safety, side effects, patient preferences, clinician experience, cost, and the invasiveness of the intervention. Given the lack of Class I evidence and Level A recommendations, particularly for a number of commonly used preventive therapies, further studies are warranted to demonstrate safety and efficacy for established and emerging therapies.

AB - Background: Cluster headache (CH), the most common trigeminal autonomic cephalalgia, is an extremely debilitating primary headache disorder that is often not optimally treated. New evidence-based treatment guidelines for CH will assist clinicians with identifying and choosing among current treatment options. Objectives: In this systematic review we appraise the available evidence for the acute and prophylactic treatment of CH, and provide an update of the 2010 American Academy of Neurology (AAN) endorsed systematic review. Methods: Medline, PubMed, and EMBASE databases were searched for double-blind, randomized controlled trials that investigated treatments of CH in adults. Exclusion and inclusion criteria were identical to those utilized in the 2010 AAN systematic review. Results and Recommendations: For acute treatment, sumatriptan subcutaneous, zolmitriptan nasal spray, and high flow oxygen remain the treatments with a Level A recommendation. Since the 2010 review, a study of sphenopalatine ganglion stimulation was added to the current guideline and has been administered a Level B recommendation for acute treatment. For prophylactic therapy, previously there were no treatments that were administered a Level A recommendation. For the current guidelines, suboccipital steroid injections have emerged as the only treatment to receive a Level A recommendation with the addition of a second Class I study. Other newly evaluated treatments since the 2010 guidelines have been given a Level B recommendation (negative study: deep brain stimulation), a Level C recommendation (positive study: warfarin; negative studies: cimetidine/chlorpheniramine, candesartan), or a Level U recommendation (frovatriptan). Conclusions: This AHS guideline can be utilized for understanding which therapies have superiority to placebo or sham treatment in the management of CH. In clinical practice, these recommendations should be considered in concert with other variables including safety, side effects, patient preferences, clinician experience, cost, and the invasiveness of the intervention. Given the lack of Class I evidence and Level A recommendations, particularly for a number of commonly used preventive therapies, further studies are warranted to demonstrate safety and efficacy for established and emerging therapies.

KW - calcium-channel blockers

KW - chronic

KW - cluster

KW - episodic

KW - evidence-based medicine

KW - guidelines

KW - headache

KW - lithium

KW - neurostimulation

KW - oxygen

KW - sphenopalatine

KW - verapamil

UR - http://www.scopus.com/inward/record.url?scp=84978696377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978696377&partnerID=8YFLogxK

U2 - 10.1111/head.12866

DO - 10.1111/head.12866

M3 - Review article

C2 - 27432623

AN - SCOPUS:84978696377

VL - 56

SP - 1093

EP - 1106

JO - Headache

JF - Headache

SN - 0017-8748

IS - 7

ER -